Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio
PR Newswire —
DOVER, Del., Feb. 2, 2026 /PRNewswire/ -- Mwyngil Therapeutics, a clinical-stage biopharmaceutical company focused on immunometabolic and neuroinflammatory diseases, today announced the initiation of a Phase 1 clinical study of BT-409, a potentially best-in-class, brain-permeable NLRP3...